Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links

Biochemistry

Volumn 48, Issue 22, 2009, Pages 4916-4925

  Zhu, Guangyu ^a   Lippard, Stephen J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; CARCINOMA CELLS; CELL CYCLE; CELLULAR FUNCTION; CELLULAR PROTEINS; CIS-PLATIN; CISPLATIN-RESISTANT CELL; DIFFERENT MECHANISMS; DNA DAMAGES; DNA DUPLEXES; DNA LIGASE; DNA PROBE; DNA-BINDING; ELECTROPHORETIC MOBILITY SHIFT ASSAY; INTERSTRAND CROSS-LINKS; NUCLEAR PROTEINS; PEPTIDE MASS FINGERPRINT; PHOTOAFFINITY LABELING; PHOTOCROSS-LINKING; SITE-SPECIFIC;

AMINES; CELL MEMBRANES; DNA; ELECTROPHORETIC MOBILITY; GENES; INORGANIC COMPOUNDS; NUCLEIC ACIDS; PLATINUM; PROTEINS;

PLATINUM COMPOUNDS;

CISPLATIN; DOUBLE STRANDED DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MUTS; XRCC1 PROTEIN;

ARTICLE; AUTORADIOGRAPHY; CELL CYCLE ARREST; CELL SYNCHRONIZATION; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA PROBE; DRUG DNA INTERACTION; DRUG STRUCTURE; FLUORESCENCE ACTIVATED CELL SORTING; GEL MOBILITY SHIFT ASSAY; HELA CELL; HUMAN; HUMAN CELL; PHOTOAFFINITY LABELING; PRIORITY JOURNAL;

CISPLATIN; CROSS-LINKING REAGENTS; DNA ADDUCTS; DNA PROBES; DNA REPAIR; HELA CELLS; HUMANS; NUCLEAR PROTEINS; NUCLEIC ACID HETERODUPLEXES; PHOTOAFFINITY LABELS; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 66649137114     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900389b     Document Type: Article

References (49)

1. Jamieson, E. R., and Lippard, S. J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498.
2. Jung, Y., and Lippard, S. J. (2007) Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107, 1387-1407.
3. Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320.
4. Vrána, O., Boudny, V., and Brabec, V. (1996) Superhelical torsion controls DNA interstrand cross-linking by antitumor cis-diammine- dichloroplatinum(II). Nucleic Acids Res. 24, 3918-3925. (Pubitemid 26385321)
5. Brabec, V., and Leng, M. (1993) DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. Proc. Natl. Acad. Sci. U.S.A. 90, 5345-5349.
6. Lemaire, M.-A., Schwartz, A., Rahmouni, A. R., and Leng, M. (1991) Interstrand cross-links are preferentially formed at the d(GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA. Proc. Natl. Acad. Sci. U.S.A. 88, 1982-1985.
7. Roberts, J. J., and Friedlos, F. (1987) Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol. Ther. 34, 215-246.
8. Corda, Y., Job, C., Anin, M.-F., Leng, M., and Job, D. (1993) Spectrum of DNA-platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. Biochemistry 32, 8582-8588. (Pubitemid 23270443)
9. Zhen, W., Link, C. J.Jr., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., and Bohr, V. A. (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol. Cell. Biol. 12, 3689-3698.
10. Sip, M., Schwartz, A., Vovelle, F., Ptak, M., and Leng, M. (1992) Distortions induced in DNA by cis-platinum interstrand adducts. Biochemistry 31, 2508-2513.
11. Malinge, J.-M., Pérez, C., and Leng, M. (1994) Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA. Nucleic Acids Res. 22, 3834-3839. (Pubitemid 24310090)
12. Huang, H., Zhu, L., Reid, B. R., Drobny, G. P., and Hopkins, P. B. (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270, 1842-1845. (Pubitemid 26007235)
13. Paquet, F., Pérez, C., Leng, M., Lancelot, G., and Malinge, J. M. (1996) NMR solution structure of a DNA decamer containing an interstrand cross-link of the antitumor drug cis-diamminedichloroplatinum(II). J. Biomol. Struct. Dyn. 14, 67-77.
14. Coste, F., Malinge, J.-M., Serre, L., Shepard, W., Roth, M., Leng, M., and Zelwer, C. (1999) Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 Å resolution: hydration at the platinated site. Nucleic Acids Res. 27, 1837-1846. (Pubitemid 29209625)
15. Huang, J.-C., Zamble, D. B., Reardon, J. T., Lippard, S. J., and Sancar, A. (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. U.S.A. 91, 10394-10398.
16. Pil, P. M., and Lippard, S. J. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237.
17. Kašpárková, J., and Brabec, V. (1995) Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins. Biochemistry 34, 12379-12387.
18. Fourrier, L., Brooks, P., and Malinge, J. M. (2003) Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein. J. Biol. Chem. 278, 21267-21275.
19. Patrick, S. M., and Turchi, J. J. (1999) Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA. J. Biol. Chem. 274, 14972-14978.
20. Patrick, S. M., Tillison, K., and Horn, J. M. (2008) Recognition of cisplatin-DNA interstrand cross-links by replication protein A. Biochemistry 47, 10188-10196.
21. Turchi, J. J., Patrick, S. M., and Henkels, K. M. (1997) Mechanism of DNA-dependent protein kinase inhibition by cis-diamminedichloroplatinum(II)- damaged DNA. Biochemistry 36, 7586-7593. (Pubitemid 27262385)
22. Zhang, C. X., Chang, P. V., and Lippard, S. J. (2004) Identification of nuclear proteins that interact with platinum-modified DNA by photoaffinity labeling. J. Am. Chem. Soc. 126, 6536-6537.
23. Sadler, P. J. (2009) Protein recognition of platinated DNA. ChemBioChem 10, 73-74.
24. Guggenheim, E. R., Xu, D., Zhang, C. X., Chang, P. V., and Lippard, S. J. (2009) Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA. ChemBioChem 10, 141-157.
25. Kane, S. A., and Lippard, S. J. (1996) Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins. Biochemistry 35, 2180-2188. (Pubitemid 26071651)
26. Maxam, A. M., and Gilbert, W. (1980) Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65, 499-560.
27. Zhang, N., Lu, X., Zhang, X., Peterson, C. A., and Legerski, R. J. (2002) hMutSβ is required for the recognition and uncoupling of psoralen interstrand cross-links in vitro. Mol. Cell.Biol. 22, 2388-2397.
28. Hofr, C., and Brabec, V. (2001) Thermal and thermodynamic properties of duplex DNA containing site-specific interstrand cross-link of antitumor cisplatin or its clinically ineffective trans isomer. J. Biol. Chem. 276, 9655-9661.
29. Mikata, Y., He, Q., and Lippard, S. J. (2001) Laser-induced photocross-linking of cisplatin-modified DNA to HMG-domain proteins. Biochemistry 40, 7533-7541. (Pubitemid 32578018)
30. 2], a metabolite of an orally active platinum anticancer drug. J. Am. Chem. Soc. 114, 5646-5654.
31. MacCoss, M. J., Wu, C. C., and Yates, J. R.III (2002) Probability-based validation of protein identifications using a modified SEQUEST algorithm. Anal. Chem. 74, 5593-5599.
32. Iyer, R. R., Pluciennik, A., Burdett, V., and Modrich, P. L. (2006) DNA mismatch repair: functions and mechanisms. Chem. Rev. 106, 302-323.
33. Mello, J. A., Acharya, S., Fishel, R., and Essigmann, J. M. (1996) The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol. 3, 579-589.
34. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. U.S.A. 93, 6443-6447.
35. Mu, D., Tursun, M., Duckett, D. R., Drummond, J. T., Modrich, P., and Sancar, A. (1997) Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol. Cell. Biol. 17, 760-769.
36. Wu, Q., Christensen, L. A., Legerski, R. J., and Vasquez, K. M. (2005) Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells. EMBO Rep. 6, 551-557. (Pubitemid 40973964)
37. + into a nuclear signal. Genes Dev. 19, 1951-1967.
38. Schreiber, V., Dantzer, F., Amé, J. C., and de Murcia, G. (2006) Poly (ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528.
39. Miknyoczki, S. J., Jones-Bolin, S., Pritchard, S., Hunter, K., Zhao, H., Wan, W., Ator, M., Bihovsky, R., Hudkins, R., Chatterjee, S., Klein-Szanto, A., Dionne, C., and Ruggeri, B. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382.
40. Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., Ferguson, D. C., Ghoreishi-Haack, N. S., Grimm, D. R., Guan, R., Han, E. K., Holley-Shanks, R. R., Hristov, B., Idler, K. B., Jarvis, K., Johnson, E. F., Kleinberg, L. R., Klinghofer, V., Lasko, L. M., Liu, X., Marsh, K. C., McGonigal, T. P., Meulbroek, J. A., Olson, A. M., Palma, J. P., Rodriguez L. E., Shi, Y., Stavropoulos, J. A., Tsurutani, A. C., Zhu, G.-D., Rosenberg, S. H., Giranda, V. L., and Frost, D. J. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737.
41. Guggenheim, E. R., Ondrus, A. E., Movassaghi, M., and Lippard, S. J. (2008) Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA. Bioorg. Med. Chem. 16, 10121-10128.
42. Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J. C., Lynch, T. J., Neuberg, D. S., and Christiani, D. C. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22, 2594-2601.
43. Weaver, D. A., Crawford, E. L., Warner, K. A., Elkhairi, F., Khuder, S. A., and Willey, J. C. (2005) ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 4, 18. (Pubitemid 41460841)
44. Thomas, J. O., and Travers, A. A. (2001) HMG1 and 2, and related "architectural" DNA-binding proteins. Trends Biochem. Sci. 26, 167-174.
45. Reddy, M. C., Christensen, J., and Vasquez, K. M. (2005) Interplay between human high mobility group protein 1 and replication protein A on psoralen-cross-linked DNA. Biochemistry 44, 4188-4195. (Pubitemid 40403958)
46. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., and Howell, S. B. (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881-4886. (Pubitemid 26374423)
47. Qin, L. F., and Ng, I. O. L. (2002) Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 175, 27-38. (Pubitemid 33153041)
48. Chu, G. (1994) Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269, 787-790.
49. Wilkins, D. E., Ng, C. E., and Raaphorst, G. P. (1997) Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Chemother. Pharmacol. 40, 159-166.